Qinghai Ji
Fudan University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Qinghai Ji as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:57 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06682117 · A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid TumorFudan University · recruiting · Treatment, Neoantigen, Vaccine · principal investigator
- Ph4NCT06195228 · A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid CancerFudan University · recruiting · Advanced Thyroid Cancer Patients Who Received Target Therapy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:57 UTC. The ranking covers the 200 most relevant of 123 PubMed records, and a shared surname and initials can bring in a namesake. All 123 on PubMed
- Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.Mol Cancer Ther · 2012423 citationsRCR 10.1
- Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/β-catenin signal pathway.PLoS One · 2013301 citationsRCR 10.2
- Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.Lancet Diabetes Endocrinol · 2014134 citationsRCR 4.7
- 130 citationsRCR 4.6
- Xiao-Chai-Hu-Tang ameliorates tumor growth in cancer comorbid depressive symptoms via modulating gut microbiota-mediated TLR4/MyD88/NF-κB signaling pathway.Phytomedicine · 2021116 citationsRCR 7.3
- Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.Thyroid · 2018101 citationsRCR 3.6
- 89 citationsRCR 3.3
- 83 citationsRCR 2.4
- 70 citationsRCR 2.1
- Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting.Int Heart J · 201161 citationsRCR 1.9